Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid
- PMID: 15966198
Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid
Abstract
We report about a 56-year-old asymptomatic female patient, who was examined in April 1991 for an increase of biochemical parameters of the liver. Based on the biochemical and serological results (abnormal cholestatic liver function tests, positive antimitochondrial antibodies) as well as liver biopsy primary biliary cirrhosis stage I was diagnosed. Therapy with ursodeoxycholic acid (12mg/kg body-weight/die) was started. Follow-up examinations indicated that cholestatic parameters had normalized and antimitochondrial antibodies became negative. In a further biopsy of the liver nearly regular liver parenchyma was demonstrated. Thus, therapy with ursodeoxycholic acid was stopped. However, in November 1992 cholestatic parameters increased again and, antimitochondrial antibodies recurred (subtype anti-M9: positive) without any clinical symptoms. Ursodeoxycholic acid therapy was reintroduced again. Within 3 months cholestatic parameters returned to normal and antimitochondrial antibodies were eliminated again. Since then ursodeoxycholic acid has been given continuously and a long-term remission as defined by clinical, serological and histological criteria could be maintained until today. This case report indicates a serological remission and a marked histological improvement in a female patient with an early stage of primary biliary cirrhosis (stage I) during therapy under ursodeoxycholic acid. It has to be discussed whether certain early stages of primary biliary cirrhosis with benign antimitochondrial antibody-profile (anti-M9: positive) respond well to long-term treatment with ursodeoxycholic acid.
Similar articles
-
Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.Hepatogastroenterology. 2002 Sep-Oct;49(47):1195-200. Hepatogastroenterology. 2002. PMID: 12239904
-
[Significance of subtype pattern of antimitochondrial antibodies in primary biliary cirrhosis for prognostic parameters and response to ursodeoxycholic acid].Schweiz Med Wochenschr. 1995 Apr 15;125(15):750-4. Schweiz Med Wochenschr. 1995. PMID: 7740290 German.
-
[Treatment of cholestatic liver diseases with ursodeoxycholic acid].Tidsskr Nor Laegeforen. 1997 Sep 30;117(23):3370-3. Tidsskr Nor Laegeforen. 1997. PMID: 9411890 Review. Norwegian.
-
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.Hepatology. 1999 Mar;29(3):644-7. doi: 10.1002/hep.510290301. Hepatology. 1999. PMID: 10051462 Clinical Trial.
-
[Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].Lakartidningen. 2002 Mar 21;99(12):1325-30. Lakartidningen. 2002. PMID: 11998165 Review. Swedish.
Cited by
-
Epidemiology and genetic epidemiology of the liver function test proteins.PLoS One. 2009;4(2):e4435. doi: 10.1371/journal.pone.0004435. Epub 2009 Feb 11. PLoS One. 2009. PMID: 19209234 Free PMC article.
-
Concept on the pathogenesis and treatment of primary biliary cirrhosis.World J Gastroenterol. 2006 Dec 7;12(45):7250-62. doi: 10.3748/wjg.v12.i45.7250. World J Gastroenterol. 2006. PMID: 17143938 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous